Cost-effectiveness of eformoterol Turbohaler® versus salmeterol Accuhaler® in children with symptomatic asthma

Respiratory Medicine

Volumn 96, Issue 4, 2002, Pages 250-258

  Everden, P ^a   Lloyd, A ^b   Hutchinson, J ^b   Plumb, J ^c  

^a Birchwood Medical Surgery   (United Kingdom)

^b Fourth Hurdle Consulting Ltd   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Asthma; Cost effectiveness; Eformoterol; Paediatric; Salmeterol; Symptom free days

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; SALMETEROL;

ADOLESCENT; ARTICLE; ASTHMA; CHILD; CHILD HOSPITALIZATION; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SYMPTOMATOLOGY; UNITED KINGDOM;

EID: 0036553449     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2001.1258     Document Type: Article

References (24)

1. The National Asthma Campaign. National Asthma Audit 1999/2000. 1999.
2. Von Mutius E. The burden of childhood asthma. Arch Dis Child 2000; 82 (Suppl 2): 2-5.
3. National Statistics Website. http://www.statistics.gov.uk/nsbase/. 2001.
4. Neville RG, Pearson MG, Richards N, et al. A cost analysis on the patterns of asthma prescribing in the UK. Eur Respir J 1999; 14: 605-609.
5. British Thoracic Society. The British Guidelines on asthma management 1995 review and position statement. Thorax 1997, 52(Suppl): S1-S21.
6. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999; 159: 941-955.
7. McCowan C, Neville RG, Thomas GE, et al. Effect of asthma and its treatment on growth: four year follow up of cohort of children from general practices in Tayside, Scotland. BMJ 1998; 316: 668-672.
8. Medici TC, Grebski E, Hacki M, Ruegsegger P, Maden C, Efthimiou J. Effect of one year treatment with inhaled fluticasone propionate or beclomethasone dipropionate on bone density and bone metabolism: a randomised parallel group study in adult asthmatic patients. Thorax 2000; 55: 375-382.
9. Lipworth BJ, Clark DJ, McFarlane LC. Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children. Thorax 1997; 52: 686-689.
10. British National Formulary [BNF]. London: British Medical Association; Royal Pharmaceutical Society of Great Britain, 2000.
11. Data on file Astra Daco [dose ranging study). Personal Communication, 2000.
12. Von Berg A, Papageorgiou Saxoni F, Wille S, Carrillo T, Kattamis C, Helms P. 3-month treatment with formoterol Turbuhaler in children with asthma. Eur Respir J 1998; 12(Suppl 29):19S.
13. Everden PR, Manion V, Reynia S. on behalf of the FACT Study Investigators' Group. Formoterol Turbuhaler reduces the need for relief medication in children with mild to moderate asthma and improves quality of life. Eur Respir Med 2001; 18(Suppl 33): 291S.
14. Netten A, Dennett J, Knight J. Unit costs of health and social care 1999. Canterbury: Personal Social Services Research Unit, 2000.
15. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6: 327-340.
16. Hoskins G, McCowan C, Neville RG, Thomas GE, Smith B, Silverman S. Risk factors and costs associated with an asthma attack. Thorax 2000; 55: 19-24.
17. Population mid-1999: Estimated resident population of the United Kingdom at mid-1999. London: Office of National Statistics, 2000.
18. Department of Health. Statistics for General Medical Practitioners in England: 1989-1999. Statistical Bulletin 2000; 8.
19. Rutten-van Molken MPMH, van Doorslaer EKA, Till MD. Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma. Pharmacoeconomics 1998; 14: 671- 684.
20. Campbell LM, Berggren F, Emmas C. The cost-effectiveness of eformoterol via Turbohaler and salmeterol via pressurised metered dose inhaler and metered dose powder inhaler in mild to moderate asthma. J Med Econ 2000; 3: 49-60.
21. Sculpher MJ, Buxton MJ. The episode free day as a composite measure of effectiveness. An illustrative example of formoterol versus salbutamol in asthma therapy. Pharmacoeconomics 1993; 4: 345-352.
22. Lundback B, Jenkins C, Price MJ, Thwaites RMA. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250mcg twice daily and budesonide 800mcg twice daily in the treatment of adults and adolescents with asthma. Respir Med 2000; 94: 724-732.
23. Barnes NC, Thwaites RMA, Price MJ. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children. Respir Med 1999; 93: 402-407.
24. Sullivan S, Elixhauser A, Buist A, Luce B, Eisenberg J, Weiss K. National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care. Am J Respir Crit Care Med 1996; 154: S84-S95.